» Articles » PMID: 15470044

Engagement of Glucocorticoid-induced TNFR Family-related Receptor on Effector T Cells by Its Ligand Mediates Resistance to Suppression by CD4+CD25+ T Cells

Overview
Journal J Immunol
Date 2004 Oct 8
PMID 15470044
Citations 192
Authors
Affiliations
Soon will be listed here.
Abstract

Nonactivated CD4+CD25+ regulatory T cells constitutively express glucocorticoid-induced TNFR family-related receptor (GITR), a TNFR family member whose engagement was presumed to abrogate regulatory T cell-mediated suppression. Using GITR-/- mice, we report that GITR engagement on CD25-, not CD25+ T cells abrogates T cell-mediated suppression. Mouse APCs constitutively express GITR ligand (GITR-L), which is down-regulated following TLR signaling in vivo. Although GITR-/-CD25- T cells were capable of mounting proliferative responses, they were incapable of proliferation in the presence of physiological numbers of CD25+ T cells. Thus, GITR-L provides an important signal for CD25- T cells, rendering them resistant to CD25+ -mediated regulation at the initiation of the immune response. The down-regulation of GITR-L by inflammatory stimuli may enhance the susceptibility of effector T cells to suppressor activity during the course of an infectious insult.

Citing Articles

Immune checkpoint inhibitors in infectious disease.

King H, Lewin S Immunol Rev. 2024; 328(1):350-371.

PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.


Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients.

Lokhande L, Nilsson D, de Matos Rodrigues J, Hassan M, Olsson L, Pyl P Cancers (Basel). 2024; 16(13).

PMID: 39001353 PMC: 11240320. DOI: 10.3390/cancers16132289.


Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting.

Moussa P, Kurzrock R, Nishizaki D, Miyashita H, Lee S, Nikanjam M Am J Cancer Res. 2024; 14(4):1634-1648.

PMID: 38726288 PMC: 11076267. DOI: 10.62347/ECED5481.


Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.

Ma Y, Shi R, Li F, Chang H Cell Commun Signal. 2024; 22(1):262.

PMID: 38715122 PMC: 11075321. DOI: 10.1186/s12964-024-01641-7.


The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).

Wang C, Biswas P, Islam A, Chen M, Chueh P Cells. 2024; 13(5.

PMID: 38474377 PMC: 10930979. DOI: 10.3390/cells13050413.